Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 06 Nov 2017 Planned End Date changed from 17 Sep 2019 to 17 May 2019.
- 06 Nov 2017 Planned primary completion date changed from 31 Aug 2018 to 17 May 2019.
- 06 Nov 2017 Status changed from not yet recruiting to recruiting.